Speaker Profile

M.D., Chief Medical Officer, Adela

Biography
Dr. Hartman is a highly trained medical oncologist with 15 years of industry experience in product development with expertise in the clinical development and commercialization of molecular diagnostics in cancer screening and oncology. With an interest in innovative technology platforms to improve patient outcomes and health care, Dr. Hartman has played a pivotal role in the development and commercialization of several molecular diagnostic tests in oncology. This includes leading the design and completion of several large scale clinical trials in early cancer detection and hereditary cancer screening. Her interest in innovative technology ultimately led her to co-found Adela to develop a best-in-class liquid biopsy test for early cancer detection and minimal residual disease detection that avoids the limitations of standard liquid biopsy approaches.


Clinical Dx Showcase:
Adela

Adela is focused on the detection of cancer through a best-in-class liquid biopsy test. Adela's methylome profiling platform has the potential to detect and classify underlying disease, including tissue of origin and histologic subtype.

Pan-Cancer Screening Using Adela’s Methylome Profiling Platform
cfMeDIP-seq is a next-generation methylation technology being developed for applications across the cancer care continuum. Technical advantages enable high sensitivity for cancer detection, tissue of origin, histologic subtyping , and identification of underlying biology through distinct patterns of methylation across the cancer methylome.

 Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative